CRNX - What's Going On With Crinetics Pharmaceuticals Stock? | Benzinga
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) shares are trading higher Tuesday. The stock appears to be moving on continued momentum after the company announced that its investigational compound met all endpoints in a Phase 3 clinical study.
What To Know:
Crinetics Pharmaceuticals announced on Sunday that paltusotine, its investigational compound, achieved positive results and met the primary endpoint and all secondary endpoints of the Phase 3 PATHFNDR-1 study.
Shares of CRNX gained more than 50% ...